Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group
- PMID: 1466089
- DOI: 10.1159/000282409
Prophylactic effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer. BLP Study Group
Abstract
A randomized controlled study was conducted in patients with superficial bladder cancer in order to investigate the safety of an orally administered (3 g/day) Lactobacillus preparation, biolactis powder (BLP), and its preventive effect on the recurrence after transurethral resection of the bladder tumor (TUR-Bt). Of 58 cases enrolled in the study 23 cases in the BLP group and 25 cases in the control group completed the study. There were no significant differences in the patient characteristics for the complete cases between the two groups. Comparison of the disease-free duration by the Kaplan-Meier method revealed that the 50% recurrence-free interval after TUR-Bt was prolonged by BLP treatment (350 days) to 1.8 times that in the control group (195 days). A significant difference between the groups was detected by the long-rank test (p = 0.03). No adverse side effect was observed. The results suggest that oral administration of BLP is useful for the prevention of the recurrence of superficial bladder cancer.
Similar articles
-
Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group.Eur Urol. 1995;27(2):104-9. doi: 10.1159/000475138. Eur Urol. 1995. PMID: 7744150 Clinical Trial.
-
Prevention of recurrence with epirubicin and lactobacillus casei after transurethral resection of bladder cancer.J Urol. 2008 Feb;179(2):485-90. doi: 10.1016/j.juro.2007.09.031. J Urol. 2008. PMID: 18076918 Clinical Trial.
-
[Treatment of superficial transitional cell bladder carcinoma. Long-term results of trial comparing transurethral resection alone and adjuvant chemotherapy with Doxorubicin].Medicina (Kaunas). 2002;38 Suppl 1:79-83. Medicina (Kaunas). 2002. PMID: 12556642 Clinical Trial. Lithuanian.
-
The biology and treatment of superficial bladder cancer.J Clin Oncol. 1984 May;2(5):505-31. doi: 10.1200/JCO.1984.2.5.505. J Clin Oncol. 1984. PMID: 6427417 Review.
-
High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.Semin Urol Oncol. 1997 Aug;15(3):147-53. Semin Urol Oncol. 1997. PMID: 9394909 Review.
Cited by
-
Probiotics and prebiotics in the elderly.Postgrad Med J. 2004 Aug;80(946):447-51. doi: 10.1136/pgmj.2003.015339. Postgrad Med J. 2004. PMID: 15299153 Free PMC article. Review.
-
Lactobacillus rhamnosus GG induces tumor regression in mice bearing orthotopic bladder tumors.Cancer Sci. 2010 Mar;101(3):751-8. doi: 10.1111/j.1349-7006.2009.01426.x. Epub 2009 Nov 6. Cancer Sci. 2010. PMID: 20015287 Free PMC article.
-
Supplementation of Probiotic Butyricicoccus pullicaecorum Mediates Anticancer Effect on Bladder Urothelial Cells by Regulating Butyrate-Responsive Molecular Signatures.Diagnostics (Basel). 2021 Dec 4;11(12):2270. doi: 10.3390/diagnostics11122270. Diagnostics (Basel). 2021. PMID: 34943506 Free PMC article.
-
Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder.Immunology. 2008 Jul;124(3):419-27. doi: 10.1111/j.1365-2567.2007.02792.x. Epub 2008 Jan 22. Immunology. 2008. PMID: 18217952 Free PMC article.
-
Body Mass Index, Diet-Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis.Bladder Cancer. 2018 Jan 20;4(1):91-112. doi: 10.3233/BLC-170147. Bladder Cancer. 2018. PMID: 29430510 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical